FTC Orders Divestitures In Impax's $700M CorePharma Buy
Impax Laboratories Inc. and private equity-owned CorePharma LLC agreed to sell CorePharma's rights to two generic drugs in order to settle Federal Trade Commission charges that Impax's $700 million proposed buyout...To view the full article, register now.
Already a subscriber? Click here to view full article